PfizerNYSE: PFE

Pfizer appears to be on its way toward stabilizing its business and winning back Wall Street's favor after the sudden decline of its Covid business. But the company is struggling to balance that with the concerns and fears of its workers.

Pfizer shares have suffered a painful slide as pandemic revenue dried up. But management is committed to maintaining and growing the dividend.

A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.

Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

Pfizer dominates the pneumococcal vaccine market. However, Merck has obtained approval for a pneumococcal vaccine Merck's new medication could become the new top seller for this indication.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company's common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024. The third-quarter 2024 cash dividend will be the 343rd consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bri.

Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.

Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.

Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.